Polysaccharide-Based Drug Conjugates for Tumor Targeting

Drug Delivery in Oncology: From Basic Research to Cancer Therapy

Volumn 2, Issue , 2011, Pages 701-746

  Saravanakumar, Gurusamy ^a   Park, Jae Hyung ^a   Kim, Kwangmeyung ^c   Kwon, Ick Chan ^b  

^a Kyung Hee University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c NONE

Author keywords

Cyclodextrin; Dextran; Drug conjugate; Polysaccharide; Tumor targeting

Indexed keywords

EID: 84887209733     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527634057.ch23     Document Type: Chapter

References (118)

1. Jain, R.K. (1996) Delivery of molecular medicine to solid tumors. Science, 271, 1079-1080.
2. Allen, T.M. and Cullis, P.R. (2004) Drug delivery systems: entering the mainstream. Science, 303, 1818-1822.
3. Park, J.H., Lee, S., Kim, J.-H., Park, K., Kim, K., and Kwon, I.C. (2008) Polymeric nanomedicine for cancer therapy. Prog. Polym. Sci., 33, 113-137.
4. Maeda, H., Seymour, L.W., and Miyamoto, Y. (1992) Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug. Chem., 3, 351-362.
5. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K. (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release, 65, 271-284.
6. Duncan, R. (2003) The dawning era of polymer therapeutics. Nat. Rev. Drug Discov., 2, 347-360.
7. Ringsdorf, H. (1975) Structure and properties of pharmacologically active polymers. J. Polym. Sci. Polym. Symp., 51, 135-153.
8. Khandare, J. and Minko, T. (2006) Polymer-drug conjugates: progress in polymeric prodrugs. Prog. Polym. Sci., 31, 359-397.
9. Larsen, C. (1989) Dextran prodrugs - structure and stability in relation to therapeutic activity. Adv. Drug Deliv. Rev., 3, 103-154.
10. Kopecek, J. and Kopecková, P. (2010) HPMA copolymers: origins, early developments, present, and future. Adv. Drug Deliv. Rev., 62, 122-149.
11. Kratz, F., Abu Ajaj, K., and Warnecke, A. (2007) Anticancer carrier-linked prodrugs in clinical trials. Expert Opin. Invest. Drugs, 16, 1037-1058.
12. Pasut, G. and Veronese, F.M. (2009) PEG conjugates in clinical development or use as anticancer agents: an overview. Adv. Drug Deliv. Rev., 61, 1177-1188.
13. Platt, V.M. and Szoka, F.C. (2008) Anticancer therapeutics: Targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharm., 5, 474-486.
14. Soyez, H., Schacht, E., and Vanderkerken, S. (1996) The crucial role of spacer groups in macromolecular prodrug design. Adv. Drug Deliv. Rev., 21, 81-106.
15. Christie, R.J. and Grainger, D.W. (2003) Design strategies to improve soluble macromolecular delivery constructs. Adv. Drug Deliv. Rev., 55, 421-437.
16. Nichifor, M. and Mocanu, G. (2006) Polysaccharide-drug conjugates as controlled drug delivery systems, in Polysaccharides for Drug Delivery and Pharmaceutical Applications (eds R.H. Marchessault, F. Ravenelle, and X.X. Zhu), Oxford University Press, New York, pp. 289-303.
17. Levi-Schaffer, F., Bernstein, A., Meshorer, A., and Arnon, R. (1982) Reduced toxicity of daunorubicin by conjugation to dextran. Cancer Treat. Rep., 66, 107-114.
18. Takakura, Y., Kaneko, Y., Fujita, T., Hashida, M., Maeda, H., and Sezaki, H. (1989) Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran I: synthesis and characterization. J. Pharm. Sci., 78, 117-121.
19. Mocanu, G., Constantin, M., and Carpov, A. (1996) Chemical reactions on polysaccharides, 5. Reaction of mesyl chloride with pullulan. Angew. Makromol. Chem., 241, 1-10.
20. Móra, M. and Pató, J. (1990) Polymeric prodrugs, 8. Synthesis and hydrolytic behaviour of dextran-bound anticancer agents. Makromol. Chem., 191, 1051-1056.
21. Aspinall, G. (1982) The Polysaccharides, Academic Press, New York.
22. Kojima, T., Hashida, M., Muranishi, S., and Sezaki, H. (1980) Mitomycin C-dextran conjugate: a novel high molecular weight pro-drug of mitomycin C. J. Pharm. Pharmacol., 32, 30-34.
23. Hashida, M., Takakura, Y., Matsumoto, S., Sasaki, H., Kato, A., Kojima, T., Muranishi, S., and Sezaki, H. (1983) Regeneration characteristics of mitomycin C-dextran conjugate in relation to its activity. Chem. Pharm. Bull., 31, 2055-2063.
24. Yoshinobu, T., Satoshi, M., Mitsuru, H., and Hitoshi, S. (1989) Physicochemical properties and antitumor activities of polymeric prodrugs of mitomycin C with different regeneration rates. J. Control. Release, 10, 97-105.
25. Takakura, Y., Takagi, A., Hashida, M., and Sezaki, H. (1987) Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm. Res., 4, 293-300.
26. Nomura, T., Saikawa, A., Morita, S., Sakaeda, T., Yamashita, F., Honda, K., Yoshinobu, T., and Hashida, M. (1998) Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoural injection. J. Control. Release, 52, 239-252.
27. Takakura, Y., Matsumoto, S., Hashida, M., and Sezaki, H. (1984) Enhanced lymphatic delivery of mitomycin C conjugated with dextran. Cancer Res., 44, 2505-2510.
28. Ueda, Y., Munechika, K., Kikukawa, A., Kanoh, Y., Yamanouchi, K., and Yokoyama, K. (1989) Comparison of efficacy, toxicity and pharmacokinetics of free adriamycin and adriamycin linked to oxidized dextran in rats. Chem. Pharm. Bull., 37, 1639-1641.
29. Munechika, K., Sogame, Y., Kishi, N., Kawabata, Y., Ueda, Y., Yuamanouchi, K., and Yokoyama, K. (1994) Tissue distribution of macromolecular conjugate, adriamycin linked to oxidized dextran, in rat and mouse bearing tumor cells. Biol. Pharmacol. Bull., 17, 1193-1198.
30. Lam, W., Chan, H., Yang, M., Cheng, S., and Fong, W. (1999) Synergism of energy starvation and dextran-conjugated doxorubicin in the killing of multidrug-resistant KB carcinoma cells. Anti-Cancer Drugs, 10, 171-178.
31. Sheldon, K., Marks, A., and Baumal, R. (1989) Sensitivity of multidrug resistant KB-C1 cells to an antibody-dextran-adriamycin conjugate. Anti-Cancer Res., 9, 637-641.
32. Kikukawa, A., Munechika, K., Ueda, Y., Yamanouchi, K., Yokoyama, K., and Tsukagoshi, S. (1990) Tissue concentration of adriamycin and adriamycin-oxidized dextran conjugate in tumor bearing rats and mice. Drug Deliv. Syst., 5, 255-260.
33. Danhauser-Riedl, S., Hausmann, E., Schick, H.-D., Bender, R., Dietzfelbinger, H., Rastetter, J., and Hanauske, A.-R. (1993) Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest. New Drugs, 11, 187-195.
34. Sugahara, S.-I., Kajiki, M., Kuriyama, H., and Kobayashi, T.-R. (2007) Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992). J. Control. Release, 117, 40-50.
35. Harada, M., Sakakibara, H., Yano, T., Suzuki, T., and Okuno, S. (2000) Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate. J. Control. Release, 69, 399-412.
36. Okuno, S., Harada, M., Yano, T., Yano, S., Kiuchi, S., Tsuda, N., Sakamura, Y., Imai, J., Kawaguchi, T., and Tsujihara, K. (2000) Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res., 60, 2988-2995.
37. Harada, M., Imai, J., Okuno, S., and Suzuki, T. (2000) Macrophage-mediated activation of camptothecin analogue T-2513-carboxymethyl dextran conjugate (T-0128): possible cellular mechanism for antitumor activity. J. Control. Release, 69, 389-397.
38. Schechter, B., Pauzner, R., Arnon, R., and Wilchek, M. (1986) Cis-platinum(II) complexes of carboxymethyl-dextran as potential antitumor agents. I. Preparation and characterization. Cancer Biochem. Biophys., 8, 277-287.
39. Nakashima, M., Ichinose, K., Kanematsu, T., Masunaga, T., Ohya, Y., Ouchi, T., Tomiyama, N., Sasaki, H., and Ichikawa, M. (1999) In vitro characteristics and in vivo plasma disposition of cisplatin conjugated with oxidized and dicarboxymethylated dextrans. Biol. Pharm. Bull., 22, 756-761.
40. Ohya, Y., Oue, H., Nagatomi, K., and Ouchi, T. (2001) Design of macromolecular prodrug of cisplatin using dextran with branched galactose units as targeting moieties to hepatoma cells. Biomacromolecules, 2, 927-933.
41. Chau, Y., Tan, F.E., and Langer, R. (2004) Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX. Bioconjug. Chem., 15, 931-941.
42. Kumar, M.N.V.R., Muzzarelli, R.A.A., Muzzarelli, C., Sashiwa, H., and Domb, A.J. (2004) Chitosan chemistry and pharmaceutical perspectives. Chem. Rev., 104, 6017-6084.
43. Rinaudo, M. (2006) Chitin and chitosan: properties and applications. Prog. Polym. Sci., 31, 603-632.
44. Aiba, S.-I. (1992) Studies on chitosan: 4. Lysozymic hydrolysis of partially N-acetylated chitosans. Int. J. Biol. Macromol., 14, 225-228.
45. Kim, J.H., Kim, Y.S., Kim, S., Park, J.H., Kim, K., Choi, K., Chung, H., Jeong, S.Y., Park, R.W., Kim, I.S., and Kwon, I.C. (2006) Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J. Control. Release, 111, 228-234.
46. Leitner, V.M., Walker, G.F., and Bernkop-Schnürch, A. (2003) Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins. Eur. J. Pharm. Biopharm., 56, 207-214.
47. Kato, Y., Onishi, H., and Machida, Y. (2000) Evaluation of N-succinyl-chitosan as a systemic long-circulating polymer. Biomaterials, 21, 1579-1585.
48. Park, J.H., Saravanakumar, G., Kim, K., and Kwon, I.C. (2010) Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv. Drug Deliv. Rev., 62, 28-41.
49. Amidi, M., Mastrobattista, E., Jiskoot, W., and Hennink, W.E. (2010) Chitosan-based delivery systems for protein therapeutics and antigens. Adv. Drug Deliv. Rev., 62, 59-82.
50. Ohya, Y., Nonomura, K., Hirai, K., and Ouchi, T. (1994) Synthesis of 6-O-carboxymethylchitin immobilizing doxorubicins through tetrapeptide spacer groups and its enzymatic release behavior of doxorubicin in vitro. Macromol. Chem. Phys., 195, 2839-2853.
51. Ohya, Y., Nonomura, K., and Ouchi, T. (1995) In vivo and in vitro antitumor activity of CM-chitin immobilized doxorubicins by lysosomal digestible tetrapeptide spacer groups. J. Bioact. Compat. Polym., 10, 223-234.
52. Davis, M.E., Chen, Z., and Shin, D.M. (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 7, 771-782.
53. Son, Y.J., Jang, J.S., Cho, Y.W., Chung, H., Park, R.W., Kwon, I.C., Kim, I.S., Park, J.Y., Seo, S.B., Park, C.R., and Jeong, S.Y. (2003) Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. J. Control. Release, 91, 135-145.
54. Park, J.H., Kwon, S., Lee, M., Chung, H., Kim, J.H., Kim, Y.S., Park, R.W., Kim, I.S., Bong Seo, S., Kwon, I.C., and Young Jeong, S. (2006) Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity. Biomaterials, 27, 119-126.
55. Lipinski, C. (2002) Poor aqueous solubility - an industry wide problem in drug discovery. Am. Pharm. Rev., 5, 82-85.
56. Lee, E., Lee, J., Lee, I.-H., Yu, M., Kim, H., Chae, S.Y., and Jon, S. (2008) Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J. Med. Chem., 51, 6442-6449.
57. Song, Y., Onishi, H., and Nagai, T. (1993) Conjugate of mitomycin C with N-succinyl-chitosan: in vitro drug release properties, toxicity and antitumor activity. Int. J. Pharm., 98, 121-130.
58. Sato, M., Onishi, H., Takahara, J., Machida, Y., and Nagai, T. (1996) In vivo drug release and antitumor characteristics of water-soluble conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan. Biol. Pharm. Bull., 19, 1170-1177.
59. Kato, Y., Onishi, H., and Machida, Y. (2004) N-succinyl-chitosan as a drug carrier: water-insoluble and water-soluble conjugates. Biomaterials, 25, 907-915.
60. Kato, Y., Onishi, H., and Machida, Y. (2000) Biological fate of highly-succinylated N-succinyl-chitosan and antitumor characteristics of its water-soluble conjugate with mitomycin C at i.v. and i.p. administration into tumor-bearing mice. Biol. Pharm. Bull., 23, 1497-1503.
61. Laurent, T. and Fraser, J. (1992) Hyaluronan. FASEB J., 6, 2397-2404.
62. Lapc̃ik, L., De Smedt, S., Demeester, J., and Chabrec̃ek, P. (1998) Hyaluronan: preparation, structure, properties, and applications. Chem. Rev., 98, 2663-2684.
63. Toole, B.P. (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer, 4, 528-539.
64. Choi, K.Y., Min, K.H., Na, J.H., Choi, K., Kim, K., Park, J.H., Kwon, I.C., and Jeong, S.Y. (2009) Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution. J. Mater. Chem., 19, 4102-4107.
65. Choi, K.Y., Chung, H., Min, K.H., Yoon, H.Y., Kim, K., Park, J.H., Kwon, I.C., and Jeong, S.Y. (2010) Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials, 31, 106-114.
66. Luo, Y. and Prestwich, G.D. (1999) Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug. Chem., 10, 755-763.
67. Akima, K., Ito, H., Iwata, Y., Matsuo, K., Watari, N., Yanagi, M., Hagi, H., Oshima, K., Yagita, A., Atomi, Y., and Tatekawa, I. (1996) Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity. J. Drug Target., 4, 1-8.
68. Cera, C., Palumbo, M., Stefanelli, S., Rassu, M., and Palu, G. (1992) Water-soluble polysaccharide-anthracycline conjugates: biological activity. Anti-Cancer Drug Des., 7, 141-151.
69. Coradini, D., Pellizzaro, C., Miglierini, G., Daidone, M.G., and Perbellini, A. (1999) Hyaluronic acid as drug delivery for sodium butyrate: improvement of the anti-proliferative activity on a breast-cancer cell line. Int. J. Cancer, 81, 411-416.
70. Coradini, D. and Perbellini, A. (2004) Hyaluronan: a suitable carrier for an histone deacetylase inhibitor in the treatment of human solid tumors. Cancer Ther., 2, 201-216.
71. Luo, Y., Ziebell, M.R., and Prestwich, G.D. (2000) A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules, 1, 208-218.
72. Thierry, B., Kujawa, P., Tkaczyk, C., Winnik, F.M., Bilodeau, L., and Tabrizian, M. (2005) Delivery platform for hydrophobic drugs: prodrug approach combined with self-assembled multilayers. J. Am. Chem. Soc., 127, 1626-1627.
73. Lee, H., Lee, K., and Park, T.G. (2008) Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity. Bioconjug. Chem., 19, 1319-1325.
74. Rosato, A., Banzato, A., De Luca, G., Renier, D., Bettella, F., Pagano, C., Esposito, G., Zanovello, P., and Bassi, P. (2006) HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol. Oncol. Semin. Orig. Invest., 24, 207-215.
75. Banzato, A., Bobisse, S., Rondina, M., Renier, D., Bettella, F., Esposito, G., Quintieri, L., Meléndez-Alafort, L., Mazzi, U., Zanovello, P., and Rosato, A. (2008) A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin. Cancer Res., 14, 3598-3606.
76. Banzato, A., Rondina, M., Meléndez-Alafort, L., Zangoni, E., Nadali, A., Renier, D., Moschini, G., Mazzi, U., Zanovello, P., and Rosato, A. (2009) Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate. Nucl. Med. Biol., 36, 525-533.
77. De Stefano, I., Battaglia, A., Zannoni, G., Prisco, M., Fattorossi, A., Travaglia, D., Baroni, S., Renier, D., Scambia, G., Ferlini, C., and Gallo, D. (2011) Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44+ human ovarian cancer xenografts. Cancer Chemother. Pharmacol., 68 (1), 107-116.
78. Casu, B. and Lindahl, U. (2001) Structure and biological interactions of heparin and heparan sulfate. Adv. Carbohydr. Chem. Biochem., 57, 159-206.
79. Vlodavsky, I., Abboud-Jarrous, G., Elkin, M., Naggi, A., Casu, B., Sasisekharan, R., and Ilan, N. (2006) The impact of heparanase and heparin on cancer metastasis and angiogenesis. Pathophysiol. Haemost. Thromb., 35, 116-127.
80. Garg, H.G., Thompson, B.T., and Hales, C.A. (2000) Structural determinants of antiproliferative activity of heparin on pulmonary artery smooth muscle cells. Am. J. Physiol., 279, L779-L789.
81. Norrby, K. (1993) Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Pathophysiol. Haemost. Thromb., 23 (Suppl. 1), 141-149.
82. Norrby, K. and Østergaard, P. (1996) Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int. J. Microcirc., 16, 8-15.
83. Wang, Y., Xin, D., Liu, K., and Xiang, J. (2009) Heparin-paclitaxel conjugatesusing mixed anhydride as intermediate: synthesis, influence of polymer structure on drug release, anticoagulant activity and in vitro efficiency. Pharm. Res., 26, 785-793.
84. Park, K., Kim, Y.-S., Lee, G., Park, R.-W., Kim, I.-S., Kim, S., and Byun, Y. (2008) Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth. Pharm. Res., 25, 2786-2798.
85. Wang, X., Li, J., Wang, Y., Cho, K.J., Kim, G., Gjyrezi, A., Koenig, L., Giannakakou, P., Shin, H.J.C., Tighiouart, M., Nie, S., Chen, Z., and Shin, D.M. (2009) HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano, 3, 3165-3174.
86. Leathers, T.D. (2002) Pullulan, in Biopolymers 6: Polysaccharides II: Polysaccharides from Eukaryotes (eds A. Steinbüchel, E.J. Vandamme, and S. De Baets), Wiley-VCH Verlag GmbH, Weinheim, pp. 1-35.
87. Shingel, K.I. (2004) Current knowledge on biosynthesis, biological activity, and chemical modification of the exopolysaccharide, pullulan. Carbohydr. Res., 339, 447-460.
88. Alban, S., Schauerte, A., and Franz, G. (2002) Anticoagulant sulfated polysaccharides: part I. Synthesis and structure-activity relationships of new pullulan sulfates. Carbohydr. Polym., 47, 267-276.
89. Kaneo, Y., Tanaka, T., Nakano, T., and Yamaguchi, Y. (2001) Evidence for receptor-mediated hepatic uptake of pullulan in rats. J. Control. Release, 70, 365-373.
90. Hosseinkhani, H., Aoyama, T., Ogawa, O., and Tabata, Y. (2002) Liver targeting of plasmid DNA by pullulan conjugation based on metal coordination. J. Control. Release, 83, 287-302.
91. Na, K., Bum Lee, T., Park, K.-H., Shin, E.-K., Lee, Y.-B., and Choi, H.-K. (2003) Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system. Eur. J. Pharm. Sci., 18, 165-173.
92. Nogusa, H., Yano, T., Okuno, S., Hamana, H., and Inoue, K. (1995) Synthesis of carboxymethylpullulan-peptide- doxorubicin conjugates and their properties. Chem. Pharm. Bull., 43, 1931-1936.
93. Lu, D., Wen, X., Liang, J., Gu, Z., Zhang, X., and Fan, Y. (2009) A pH-sensitive nano drug delivery system derived from pullulan/doxorubicin conjugate. J. Biomed. Mater. Res., 89B, 177-183.
94. Priego-Jimenéz, R., Peña, C., Ramírez, O.T., and Galindo, E. (2005) Specific growth rate determines the molecular mass of the alginate produced by Azotobacter vinelandii. Biochem. Eng. J., 25, 187-193.
95. Otterlei, M., Østgaard, K., Skjåk-Bræk, G., Smidsrød, O., Soon-Shiong, P., and Espevik, T. (1991) Induction of cytokine production from human monocytes stimulated with alginate. J. Immunother., 10, 286-291.
96. Fujihara, M. and Nagumo, T. (1992) The effect of the content of d-mannuronic acid and l-guluronic acid blocks in alginates on antitumor activity. Carbohydr. Res., 224, 343-347.
97. Morgan, S.M., Al-Shamkhani, A., Callant, D., Schacht, E., Woodley, J.F., and Duncan, R. (1995) Alginates as drug carriers: covalent attachment of alginates to therapeutic agents containing primary amine groups. Int. J. Pharm., 122, 121-128.
98. Al-Shamkhani, A. and Duncan, R. (1995) Synthesis, controlled release properties and antitumour activity of alginate-cis-aconityl-daunomycin conjugates. Int. J. Pharm., 122, 107-119.
99. Adams, M.K. and Douglas, C. (1963) Arabinogalactan - a review of the literature. Tech. Assoc. Pulp Pap. Ind., 46, 544-548.
100. Groman, E.V., Enriquez, P.M., Jung, C., and Josephson, L. (1994) Arabinogalactan for hepatic drug delivery. Bioconjug. Chem., 5, 547-556.
101. Ehrenfreund-Kleinman, T., Golenser, J., and Domb, A.J. (2004) Conjugation of amino-containing drugs topolysaccharides by tosylation: amphotericin B-arabinogalactan conjugates. Biomaterials, 25, 3049-3057.
102. Pinhassi, R.I., Assaraf, Y.G., Farber, S., Stark, M., Ickowicz, D., Drori, S., Domb, A.J., and Livney, Y.D. (2009) Arabinogalactan-folic acid-drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells. Biomacromolecules, 11, 294-303.
103. Sinha, V.R. and Kumria, R. (2001) Polysaccharides in colon-specific drug delivery. Int. J. Pharm., 224, 19-38.
104. Tang, X.-H., Xie, P., Ding, Y., Chu, L.-Y., Hou, J.-P., Yang, J.-L., Song, X., and Xie, Y.-M. (2010) Synthesis, characterization, and in vitro and in vivo evaluation of a novel pectin-adriamycin conjugate. Bioorg. Med. Chem., 18, 1599-1609.
105. Cao, Y., Gu, Y., Ma, H., Bai, J., Liu, L., Zhao, P., and He, H. (2010) Self-assembled nanoparticle drug delivery systems from galactosylated polysaccharide-doxorubicin conjugate loaded doxorubicin. Int. J. Biol. Macromol., 46, 245-249.
106. Ouchi, T., Tada, M., Matsumoto, M., Ohya, Y., Hasegawa, K., Arai, Y., Kadowaki, K., Akao, S., Matsumoto, T., Suzuki, S., and Suzuki, M. (1998) Design of macromolecular prodrug of 5-fluorouracil using N-acetylpolygalactosamine as a targeting carrier to hepatoma. React. Funct. Polym., 37, 235-244.
107. Ouchi, T., Tada, M., Matsumoto, M., Ohya, Y., Hasegawa, K., Arai, Y., Kadowaki, K., Akao, S., Matsumoto, T., Suzuki, S., and Suzuki, M. (1998) Design of lysosomotropic macromolecular prodrug of doxorubicin using N-acetyl-a-1,4-polygalactosamine as a targeting carrier to hepatoma tissue. J. Bioact. Compat. Polym., 13, 257-269.
108. Li, J. and Loh, X.J. (2008) Cyclodextrin-based supramolecular architectures: syntheses, structures, and applications for drug and gene delivery. Adv. Drug Deliv. Rev., 60, 1000-1017.
109. Davis, M.E. and Brewster, M.E. (2004) Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov., 3, 1023-1035.
110. van de Manakker, F., Vermonden, T., van Nostrum, C.F., and Hennink, W.E. (2009) Cyclodextrin-based polymeric materials: synthesis, properties, and pharmaceutical/biomedical applications. Biomacromolecules, 10, 3157-3175.
111. Harada, A., Takashima, Y., and Yamaguchi, H. (2009) Cyclodextrin-based supramolecular polymers. Chem. Soc. Rev., 38, 875-882.
112. Heidel, J.D. (2006) Linear cyclodextrin-containing polymers and their use as delivery agents. Expert Opin. Drug Deliv., 3, 641-646.
113. Cheng, J., Khin, K.T., Jensen, G.S., Liu, A., and Davis, M.E. (2003) Synthesis of linear, ß-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug. Chem., 14, 1007-1017.
114. Davis, M.E. (2009) Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv. Drug Deliv. Rev., 61, 1189-1192.
115. Schluep, T., Cheng, J., Khin, K., and Davis, M. (2006) Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother. Pharmacol., 57, 654-662.
116. Schluep, T., Hwang, J., Cheng, J., Heidel, J.D., Bartlett, D.W., Hollister, B., and Davis, M.E. (2006) Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res., 12, 1606-1614.
117. Schluep, T., Hwang, J., Hildebrandt, I.J., Czernin, J., Choi, C.H.J., Alabi, C.A., Mack, B.C., and Davis, M.E. (2009) Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc. Natl. Acad. Sci. USA, 106, 11394-11399.
118. Numbenjapon, T., Wang, J., Colcher, D., Schluep, T., Davis, M.E., Duringer, J., Kretzner, L., Yen, Y., Forman, S.J., and Raubitschek, A. (2009) Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin. Cancer Res., 15, 4365-4373.